Progyny Past Earnings Performance
Past criteria checks 2/6
Progyny has been growing earnings at an average annual rate of 14.9%, while the Healthcare industry saw earnings growing at 2.1% annually. Revenues have been growing at an average rate of 29.6% per year. Progyny's return on equity is 11.2%, and it has net margins of 4.3%.
Key information
14.94%
Earnings growth rate
14.43%
EPS growth rate
| Healthcare Industry Growth | 8.50% |
| Revenue growth rate | 29.57% |
| Return on equity | 11.24% |
| Net Margin | 4.33% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Progyny, Inc.'s (NASDAQ:PGNY) CEO Will Probably Struggle To See A Pay Rise This Year
May 16
The Price Is Right For Progyny, Inc. (NASDAQ:PGNY)
May 13At US$22.90, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Apr 25Progyny, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Mar 02The Play On Progyny: Don't Chase, But Watch And Wait
Feb 06Capital Allocation Trends At Progyny (NASDAQ:PGNY) Aren't Ideal
Jan 30Progyny: The Growth Story Remains Intact
Jan 15Progyny, Inc.'s (NASDAQ:PGNY) P/E Is Still On The Mark Following 28% Share Price Bounce
Jan 12Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Jan 03The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
Dec 31Progyny: Rating Downgrade On Uncertain Growth Outlook
Nov 26Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively
Nov 21Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
Nov 18Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital
Oct 21Progyny: Poor Year Raises Concerns For Future (Downgrade)
Oct 15Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors
Sep 29
Expanding Market Reach And Enhancing Services Spur Optimistic Revenue And Profit Forecasts
Sep 11 Anticipated decrease in ART cycle utilizations may negatively affect revenue due to lower fertility treatment rates.Progyny: Downgrading As Uncertainties Increase
Aug 15Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing
Aug 11At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Jul 20Progyny: Recent Stock Decline Provides Buying Opportunity
Jul 12Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall
Jun 23Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore
Jun 10Progyny: No Change To Long-Term Outlook
Jun 04Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price
Apr 29Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Apr 03Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Mar 15Progyny: Long-Term Thesis Still Intact
Mar 09Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher
Mar 01Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable
Jan 07Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Dec 11Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Nov 08Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Aug 24There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital
Aug 06Revenue & Expenses Breakdown
How Progyny makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 1,213 | 52 | 194 | 0 |
| 31 Dec 24 | 1,167 | 54 | 186 | 0 |
| 30 Sep 24 | 1,139 | 57 | 181 | 0 |
| 30 Jun 24 | 1,133 | 63 | 179 | 0 |
| 31 Mar 24 | 1,108 | 61 | 177 | 0 |
| 31 Dec 23 | 1,089 | 62 | 177 | 0 |
| 30 Sep 23 | 1,033 | 52 | 175 | 0 |
| 30 Jun 23 | 957 | 49 | 165 | 0 |
| 31 Mar 23 | 873 | 43 | 155 | 0 |
| 31 Dec 22 | 787 | 30 | 144 | 0 |
| 30 Sep 22 | 700 | 42 | 128 | 0 |
| 30 Jun 22 | 617 | 46 | 113 | 0 |
| 31 Mar 22 | 551 | 56 | 96 | 0 |
| 31 Dec 21 | 501 | 66 | 80 | 0 |
| 30 Sep 21 | 473 | 90 | 68 | 0 |
| 30 Jun 21 | 450 | 78 | 61 | 0 |
| 31 Mar 21 | 386 | 58 | 56 | 0 |
| 31 Dec 20 | 345 | 46 | 62 | 0 |
| 30 Sep 20 | 310 | 3 | 49 | 0 |
| 30 Jun 20 | 272 | -10 | 45 | 0 |
| 31 Mar 20 | 264 | -5 | 41 | 0 |
| 31 Dec 19 | 230 | -9 | 36 | 0 |
| 30 Sep 19 | 194 | -6 | 30 | 0 |
| 30 Jun 19 | 160 | 1 | 27 | 0 |
| 31 Mar 19 | 130 | -4 | 24 | 0 |
| 31 Dec 18 | 105 | -6 | 23 | 0 |
| 31 Dec 17 | 49 | -13 | 18 | 0 |
Quality Earnings: PGNY has high quality earnings.
Growing Profit Margin: PGNY's current net profit margins (4.3%) are lower than last year (5.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PGNY has become profitable over the past 5 years, growing earnings by 14.9% per year.
Accelerating Growth: PGNY's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PGNY had negative earnings growth (-14.3%) over the past year, making it difficult to compare to the Healthcare industry average (16.8%).
Return on Equity
High ROE: PGNY's Return on Equity (11.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 22:17 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Progyny, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhilin Long | Berenberg |
| Nisala Weerasuriya | Berenberg |
| Allen Lutz | BofA Global Research |